亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Clinical study of camrelizumab combined with docetaxel and carboplatin as a neoadjuvant treatment for locally advanced oesophageal squamous cell carcinoma

医学 多西紫杉醇 卡铂 养生 内科学 新辅助治疗 肿瘤科 外科 化疗 存活率 完全响应 不利影响 胃肠病学 癌症 顺铂 乳腺癌
作者
Guoliang Zhang,Qi Zhu,Teng Ma,Chen-Gang Weng,Dandan Zhang,Hui Zeng,Tao Wang,Feng Gao,Mi Liu,Rui Wang
出处
期刊:Diseases of The Esophagus [Oxford University Press]
卷期号:37 (4)
标识
DOI:10.1093/dote/doad073
摘要

Summary Herein, we aimed to evaluate the efficacy and safety of camrelizumab combined with docetaxel and carboplatin as a neoadjuvant treatment for locally advanced oesophageal squamous cell carcinoma (OSCC). Fifty-one patients with OSCC, treated from July 2020 to October 2022, were analyzed. Of them, 41 patients underwent surgery 4–8 weeks after undergoing two cycles of camrelizumab (200 mg IV Q3W) combined with docetaxel (75 mg/m2 IV Q3W) and carboplatin (area under the curve = 5–6 IV Q3W). The primary endpoint was the pathological complete response rate. All 51 patients (100%) experienced treatment-related grades 1–2 adverse events, and 2 patients (3.9%) experienced grade 4 events (including elevated alanine transaminase/aspartate transferase levels and Guillain–Barre syndrome). Fifty patients were evaluated for the treatment efficacy. Of them, 13 achieved complete response, and the objective response rate was 74%. Only 41 patients underwent surgical treatment. The pathological complete response rate was 17.1%, the major pathological response rate was 63.4%, and the R0 resection rate was 100%. Approximately 22% of the patients had tumor regression grades 0. Eight patients (19.5%) developed surgery-related complications. The median follow-up time was 18 months (range: 3–29 months). Four patients experienced disease progression, while four died. The median disease-free survival and overall survival were not reached. Camrelizumab combined with docetaxel and carboplatin is an effective and safe neoadjuvant treatment for locally advanced OSCC. This regimen may afford a potential strategy to treat patients with locally advanced OSCC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Enchanted完成签到,获得积分10
2秒前
丁爽完成签到,获得积分10
9秒前
11秒前
允怡发布了新的文献求助80
16秒前
yangon发布了新的文献求助10
17秒前
Huang2547完成签到 ,获得积分10
21秒前
慕青应助AllenWalker采纳,获得10
21秒前
月军完成签到,获得积分10
22秒前
yangon完成签到,获得积分10
29秒前
47秒前
Puan发布了新的文献求助30
48秒前
完美世界应助科研通管家采纳,获得10
52秒前
在水一方应助科研通管家采纳,获得10
52秒前
53秒前
1粒发布了新的文献求助10
59秒前
科目三应助冉亦采纳,获得20
1分钟前
1分钟前
冉亦发布了新的文献求助20
1分钟前
yyan完成签到,获得积分10
1分钟前
天才鱼完成签到 ,获得积分10
1分钟前
华仔应助1粒采纳,获得10
1分钟前
水晶鞋完成签到 ,获得积分10
2分钟前
Nakacoke77完成签到,获得积分10
2分钟前
隐形曼青应助科研通管家采纳,获得10
2分钟前
Ava应助科研通管家采纳,获得30
2分钟前
砂浆黏你完成签到,获得积分10
3分钟前
3分钟前
3分钟前
3分钟前
FashionBoy应助cheng采纳,获得10
3分钟前
悠悠发布了新的文献求助10
3分钟前
无与伦比完成签到 ,获得积分10
3分钟前
叶子完成签到 ,获得积分10
3分钟前
kdjm688完成签到,获得积分10
3分钟前
3分钟前
悠悠完成签到,获得积分10
3分钟前
cheng完成签到,获得积分10
3分钟前
轮胎配方发布了新的文献求助30
3分钟前
细腻的甜瓜完成签到,获得积分10
3分钟前
sjyu1985完成签到 ,获得积分10
3分钟前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
юрские динозавры восточного забайкалья 800
English Wealden Fossils 700
An Introduction to Geographical and Urban Economics: A Spiky World Book by Charles van Marrewijk, Harry Garretsen, and Steven Brakman 600
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3154858
求助须知:如何正确求助?哪些是违规求助? 2805656
关于积分的说明 7865582
捐赠科研通 2463838
什么是DOI,文献DOI怎么找? 1311626
科研通“疑难数据库(出版商)”最低求助积分说明 629654
版权声明 601832